University of California has described tropane derivatives acting as 5-HT2 and muscarinic receptor ligands reported to be useful for the treatment of psychiatric disorders, depression, ...

A Vanderbilt University patent discloses new muscarinic M4 receptor positive allosteric modulators and agonists reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, ...

The latest candidate to move into phase 2 is NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is the most advanced candidate in a $2.6 billion alliance with Neurocrine signed ...

Atropine therapy has a direct treatment effect on choroidal thickness, which cannot be fully explained by axial length or SER changes.

In preliminary studies, we discovered that selected typical and atypical antipsychotic drugs interacted with virtually every biogenic amine receptor tested, in confirmation of many prior studies ...

As per the Brain and Behavior Research Foundation, it combines two compounds called xanomeline and trospium chloride. This is ...

There are five subtypes of muscarinic receptor (M1–M5) that are expressed in different tissues and have diverse roles in processes such as cognition, salivation, sight, and bowel function.

Nxera and Neurocrine entered a collaboration and licensing agreement in 2021 to develop a portfolio of novel clinical and preclinical subtype-selective muscarinic M4, M1 and dual M1/M4 receptor ...

These compounds are: NBI-1117570 (a dual M1 / M4 agonist) NBI-1117567 (an M1-preferring agonist) NBI-1117569 (an M4-preferring agonist) Nxera and Neurocrine entered a collaboration and licensing ...

Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...